Literature DB >> 29974555

Recurrence after fertility-preserving surgery for low-grade endometrial stromal sarcoma.

Tzu-Hsuan Chin1,2, Gigin Lin2,3, Ren-Chin Wu2,4, Chyong-Huey Lai1,2.   

Abstract

Considering the characteristics of low-grade endometrial stromal sarcoma (ESS), such as relative indolent course, younger age at diagnosis and favorable prognosis, the fertility-preserving management of low-grade ESS has been described by several authors. We report a 34-year-old female with stage IB low-grade ESS who developed recurrence 7 years after neoadjuvant high-dose progestin therapy followed by fertility-preserving surgery and postoperative progestin therapy. The patient stopped progestin therapy and was disease free for 4 years after diagnosis but experienced recurrence with peritoneal dissemination at 7 years. Considering the tendency of late recurrence, long-term surveillance is necessary to ensure timely action. Long-term progestin treatment might be considered after complete remission even beyond 5 years. We performed a literature review and found that many of the cases did not meet solid pathological criteria of low-grade ESS. The diagnostic criteria of low-grade ESS (vs endometrial stromal nodule) should be deliberately documented for future studies of this rare disease.
© 2018 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  endometrial stromal sarcoma; fertility-preserving therapy; neoadjuvant; progestin; recurrence

Mesh:

Substances:

Year:  2018        PMID: 29974555     DOI: 10.1111/jog.13695

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  2 in total

1.  Fertility-sparing management of low-grade endometrial stromal sarcoma: analysis of an institutional series, a population-based analysis and review of the literature.

Authors:  Yawen Zheng; Qihui Yin; Xingsheng Yang; Ruiying Dong
Journal:  Ann Transl Med       Date:  2020-11

2.  Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma.

Authors:  Szymon Piątek; Iwona Szymusik; Anna Dańska-Bidzińska; Mariusz Ołtarzewski; Gabriela Trojan; Mariusz Bidziński
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.